Inferra AI / Company / NBIX
Neurocrine Biosciences Inc.
NBIX · Health Care
Last earnings Jul 31, 2026
Key results
EPSquarter
$108 million
Second quarter 2025 GAAP net income and earnings per share were $108 million and $1.06, respectively, compared with $65 million and $0.63, respectively, for second quarter 2024.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
Second quarter 2025 Non-GAAP net income and earnings per share were $166 million and $1.65, respectively, compared with $169 million and $1.63, respectively, for second quarter 2024.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
AI analysis
Q2 2025 · reported Jul 30, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance · company-stated
No guidance located in the held release
Capital allocation
As of June 30, 2025, the Company has repurchased $168 million of its common stock, including $18 million during the second quarter of 2025, and has $332 million remaining under the Board authorized program.
To minimize the risks related to cash and cash equivalents and investments in available-for-sale debt securities, we have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.
Event summary
Neurocrine Biosciences Inc. Q2 2025 — Second quarter 2025 GAAP net income and earnings per share were $108 million and $1.06, respectively, compared with $65 million and $0.63, respectively, for second quarter 2024.
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
As of June 30, 2025, the Company has repurchased $168 million of its common stock, including $18 million during the second quarter of 2025, and has $332 million remaining under the Board authorized program.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
To minimize the risks related to cash and cash equivalents and investments in available-for-sale debt securities, we have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
As of June 30, 2026 and December 31, 2025, we held available-for-sale debt securities with a total fair value of $ 139.6 million and $ 335.1 million, respectively, that were in unrealized loss positions totaling $ 0.7 million and $ 0.6 million, respectively.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Available-for-sale debt securities that had been in unrealized loss positions for longer than twelve months were not significant as of June 30, 2026 or December 31, 2025.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Unrealized losses on available-for-sale debt securities are primarily caused by changes in interest rates.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Our investments in available-for-sale debt securities are of high credit quality, and we do not intend to sell these investments and it is not more likely than not that we will be required to sell these investments before their maturity.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Strategy & priorities
In Q3, expanded formulary access for INGREZZA, further enhancing coverage from Q2 expansion to now include approximately 70% of tardive dyskinesia and Huntington s disease Medicare beneficiaries to support long-term growth.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
Increased SG A expense including incremental investment in CRENESSITY related headcount and launch activities and continued investment in INGREZZA, including the expansion of the psychiatry and long-term care sales teams in September 2024.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
SG A guidance range reflects expense for ongoing commercial initiatives supporting INGREZZA growth and the launch of CRENESSITY.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
However, if we and Voyager elect to focus on an indication other than Parkinson s disease prior to Voyager s receipt of top-line data from a first clinical trial for Parkinson s disease, then Voyager may elect to exercise such co-development and co-commercialization rights after the later of: (i) Voyager s receipt of top-line data from the first clinical trial of a product that is the subject of the GBA1 Program or (ii) the date we and Voyager decide not to pursue Parkinson s disease as an indication 17 for development under the GBA1 Program.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Risks & headwinds
Forward-Looking Statements In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties.
SEC original ↗Neurocrine Biosciences Inc. — Earnings release (8-K exhibit)EX-99Jul 30, 2025
Legal Proceedings 31 Item 1A.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Either party may terminate the agreement, subject to specified conditions, (i) in the event of material breach by the other party, subject to a cure period, (ii) if the other party challenges the validity or enforceability of certain intellectual property rights, subject to a cure period, or (iii) if the other party becomes insolvent or takes certain actions related to insolvency.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Takeda may terminate the Restated Takeda Agreement, subject to specified conditions, (i) if we challenge the validity or enforceability of certain Takeda intellectual property rights or (ii) on a target class-by-target class basis, in the event that we do not conduct any material development or commercialization activities with respect to any licensed product within such target class for a specified continuous period.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Subject to a cure period, either party may terminate the Restated Takeda Agreement in the event of any material breach, solely with respect to the target class of a licensed product to which such material breach relates, or in its entirety in the event of any material breach that relates to all licensed products, or if either party challenges the validity or enforceability of certain intellectual property rights.
SEC original ↗Neurocrine Biosciences Inc. — 10-Q Quarterly report10-QJul 31, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
25 documents- Q2 2026
- 8-KNBIX
Sep 28, 2026
- 8-K/ANBIX
- 10-QNBIX
- 8-KNBIX
Jul 30, 2026
- Q1 2026
- 8-KNBIX
May 28, 2026
- 8-KNBIX
May 18, 2026
- 10-QNBIX
- 8-KNBIX
- 8-KNBIX
- Q4 2025
- 10-KNBIX
Feb 11, 2026
- 8-KNBIX
Feb 11, 2026
- Q3 2025
- 8-KNBIX
Nov 24, 2025
- 10-QNBIX
- 8-KNBIX
Oct 28, 2025
- Q2 2025
- 10-QNBIX
- 8-KNBIX
Jul 30, 2025
- Q1 2025
- 8-KNBIX
May 30, 2025
- 8-KNBIX
May 22, 2025
- 10-QNBIX
- 8-KNBIX
- 8-KNBIX
- Q4 2024
- 10-KNBIX
Feb 10, 2025
- 8-KNBIX
- 8-KNBIX
Jan 27, 2025
- Q3 2024
- 8-KNBIX
Dec 20, 2024
Earnings releases
9 documentsPresentations
0 documentsNo presentations for Neurocrine Biosciences Inc. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Neurocrine Biosciences Inc. are held in this edition of the library.
Mentioned by
5 companiesOther tracked companies whose held documents mention Neurocrine Biosciences Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.
“…EX-99.1 3 d94926dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics Strengthens Neurocrine’s rare disease portfolio with VYKAT … … impacts to N”
Apollo Global Management (APO)
“…Date”), Neurocrine Biosciences, Inc. (“Neurocrine” or the “Company”) completed the previously announced acquisition (the “Acquisition” or “Transaction”) of Soleno Thera”
“lion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO , July 30, 2026 – Neurocrine Biosciences, Inc.… …income taxes 17.8 52.0 66.7 58.8 Net income $ 144.4 $ 107.5 $ 342.3 $ 115.4 Earnings per share, basic $ 1.43 $ 1.09 $ 3.4”
“…EX-99.1 3 d94926dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics Strengthens Neurocrine’s rare disease portfolio with VYKAT … … impacts to N”
“REZZA ® (valbenazine) Net Sales Guidance of $2.7 - $2.8 Billion SAN DIEGO , May 5, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today … … therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interco”
See also the earnings calendar for every tracked company’s next earnings date.